OrbiMed’s Prelude Therapeutics PRLD Stock Holding History

OrbiMed’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.2M	Buy	13,724,571 +2,815,315	+26%	+$12.3M	1.36%	17
2026 Q1	$37.3M	Hold	10,909,256	–	–	0.74%	40
2025 Q4	$31.6M	Hold	10,909,256	–	–	0.65%	46
2025 Q3	$15.7M	Hold	10,909,256	–	–	0.37%	61
2025 Q2	$8.83M	Hold	10,909,256	–	–	0.22%	63
2025 Q1	$8.38M	Hold	10,909,256	–	–	0.2%	67
2024 Q4	$13.9M	Hold	10,909,256	–	–	0.29%	63
2024 Q3	$22.6M	Hold	10,909,256	–	–	0.41%	62
2024 Q2	$41.6M	Hold	10,909,256	–	–	0.82%	38
2024 Q1	$51.7M	Hold	10,909,256	–	–	0.95%	37
2023 Q4	$46.6M	Hold	10,909,256	–	–	0.93%	40
2023 Q3	$33.7M	Hold	10,909,256	–	–	0.72%	52
2023 Q2	$49.1M	Buy	10,909,256 +869,565	+9%	+$5.2M	0.89%	41
2023 Q1	$57.2M	Hold	10,039,691	–	–	1.12%	28
2022 Q4	$60.6M	Hold	10,039,691	–	–	1.16%	31
2022 Q3	$66.4M	Hold	10,039,691	–	–	1.23%	27
2022 Q2	$52.4M	Hold	10,039,691	–	–	0.95%	35
2022 Q1	$69.3M	Hold	10,039,691	–	–	1.12%	32
2021 Q4	$125M	Hold	10,039,691	–	–	1.61%	21
2021 Q3	$314M	Hold	10,039,691	–	–	3.45%	2
2021 Q2	$287M	Hold	10,039,691	–	–	2.91%	6
2021 Q1	$435M	Sell	10,039,691 -5,555,186	-36%	-$369M	4.07%	3
2020 Q4	$1.12B	Hold	15,594,877	–	–	9.76%	1
2020 Q3	$470M	Buy	+15,594,877	New	+$440M	5.91%	1

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OrbiMed's PRLD Position: Q2 2026 in Review

OrbiMed increased its Prelude Therapeutics (PRLD) stake by 26% in Q2 2026, buying an estimated $12.3M and bringing the position to 13,724,571 shares worth $73.2M. The position accounts for 1.36% of the portfolio, ranked #17.

OrbiMed first reported a position in PRLD in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.12B in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

OrbiMed held 13,724,571 shares of Prelude Therapeutics worth $73.2M as of Q2 2026.
OrbiMed bought 2,815,315 Prelude Therapeutics shares in Q2 2026, an estimated $12.3M.
Prelude Therapeutics made up 1.36% of OrbiMed's portfolio in Q2 2026, its #17 holding.
OrbiMed first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 24 quarters since.
OrbiMed's Prelude Therapeutics position peaked at $1.12B in Q4 2020.
75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.